ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
KAT6A regulates osteoclast differentiation and bone resorption through TET1-mediated TRPV4 expression.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Osteoclast differentiation plays a crucial role in osteoporosis (OP) pathogenesis, yet the regulatory mechanisms remain poorly understood. Lysine acetyltransferase KAT6A, a member of the myeloid-lymphoid or mixed-lineage leukemia (MYST) family, regulates gene expression through histone H3 acetylation. This study investigated the role of KAT6A in osteoclast differentiation and elucidated regulatory mechanisms. Serum samples from osteoporosis patients and healthy controls were analyzed for KAT6A expression. An ovariectomy (OVX) mouse model and receptor activator of nuclear factor kappa-B ligand (RANKL)-induced differentiation system using bone marrow macrophages (BMMs) and RAW264.7 cells were employed. KAT6A knockdown was achieved using short hairpin RNA (shRNA) vectors, with rescue experiments using Transient Receptor Potential Vanilloid 4 (TRPV4) and Tet1 overexpression. Osteoclast differentiation was assessed by tartrate-resistant acid phosphatase (TRAP) staining, phalloidin staining, and osteoclast marker expression analysis (TRAP, c-Fos, NFATc1). Chromatin immunoprecipitation (ChIP) assays were used to investigate transcriptional regulatory mechanisms.KAT6A was significantly elevated in osteoporosis patients compared with controls. In the OVX model, KAT6A knockdown ameliorated bone loss, improving bone volume/total volume (BV/TV), trabecular thickness (Tb.Th), and trabecular number (Tb.N), while reducing trabecular separation (Tb.Sp). KAT6A depletion suppressed osteoclast differentiation markers and reduced TRAP-positive cell formation. Mechanistically, KAT6A directly bound to the Tet1 promoter region, enhancing H3K9 acetylation and RNA polymerase II recruitment, and upregulating Tet1 expression. Tet1 associated with the TRPV4 gene region and appeared to promote its transcription, suggesting potential transcriptional regulation. Overexpression of either Tet1 or TRPV4 rescued the KAT6A knockdown-induced osteoclast differentiation inhibition. KAT6A promotes osteoclast differentiation through a regulatory cascade involving Tet1-mediated TRPV4 upregulation, which identifying KAT6A as a potential therapeutic target for osteoporosis treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.